Dina YuanSheng Completes Pre-A+ Financing Led by Panlin Capital to Advance Targeted Delivery Based on DNA Nano-Carriers

VCBeat has learned that Hangzhou Dina Yuansheng Biotechnology Co., Ltd. (“Dina Yuansheng”) recently completed a Pre-A+ financing round worth tens of millions of yuan, exclusively invested by Panlin Capital, with Xinghan Capital serving as the exclusive financial advisor for the second consecutive time. Previously, the company secured multiple rounds of financing within one year, including an angel round led by Taiyu Investment and a Pre-A round led by Qiji Investment, with follow-on investments from Jiliuling Fund and Muren Investment. This latest funding will further consolidate the company’s technological advantages in the field of DNA nano-targeted carriers and advance R&D efforts across multiple pipelines, including oncology, metabolic diseases, and vaccines.

Hangzhou Dina Yuansheng Biotechnology Co., Ltd. was established in May 2022. Guided by its mission to “innovate biotechnology and safeguard life and health,” the company focuses on the development of novel nucleic acid self-assembly technologies. Leveraging this platform, it develops organ- and cell-targeted nanomedicines to achieve precise, efficient, and safe delivery of various therapeutic modalities—including nucleic acid drugs, small-molecule drugs, and protein therapeutics—within the human body. Notably, in the field of small nucleic acid drug delivery, the company’s next-generation delivery platform, DNA nanocarriers, has demonstrated significant potential in combining safety with targeting capabilities, offering a promising solution to the industry-wide challenge of extrahepatic targeted delivery for small nucleic acid therapeutics.

Dr. Ding Baoquan, the company’s founder, and his team possess extensive expertise in the design and development of nanodrug delivery systems. They have published more than 100 scientific papers in prestigious international journals, including Nature Materials, Nature Biotechnology, and Nature Communications. Previously, the team achieved the first-ever application of DNA nanomachines for tumor therapy at the in vivo level (Nat. Biotechnol., 2018, 36, 258), a breakthrough recognized as one of the “Top Ten Scientific Advances in China” in 2018. Additionally, the team designed and developed a DNA nanomachine vaccine that demonstrated robust therapeutic efficacy and long-term immune memory in cancer immunotherapy (Nat. Mater., 2021, 20, 421). This achievement was included in the 2020 “Innovation China” Pioneer Technology List, and domestic as well as PCT patents have been filed for the technology.

Currently, the company has established a multidisciplinary team comprising dozens of professionals in R&D, process development, and quality management to vigorously advance its pipeline development. Leveraging its advantages in vector targeting technology, Hangzhou Dina Yuansheng Biotechnology Co., Ltd. has implemented a robust pipeline layout across therapeutic areas including oncology, metabolic diseases, and vaccines. The delivery vectors have yielded multi-dimensional safety data in animal studies, and the core pipeline candidates have progressed to the Preclinical Candidate (PCC) confirmation stage.

Dr. Ding Baoquan, Founder and Chief Scientist of Dina Yuansheng, stated thatDina Yuansheng’s DNA nanocarriers represent a novel drug delivery platform. We are honored that our new technology has gained the recognition and support of Panlin Capital, a professional and influential venture capital firm specializing in biotechnology. With the backing of Panlin Capital, Dina Yuansheng will build upon its expertise in the programmed design of self-assembling nucleic acid nanocarriers to further validate the targeting capabilities of these nano-drug carriers in non-hepatic organs, including the kidneys, lungs, and brain. Leveraging this round of financing, the company will accelerate CMC (Chemistry, Manufacturing, and Controls) development and preclinical studies, aiming to address unmet clinical needs while steadily advancing R&D across multiple pipelines, including oncology, metabolic diseases, and vaccines. By leveraging our decades of technological accumulation, we remain committed to our corporate mission of “innovating biotechnology to safeguard life and health,” striving to build a globally leading intelligent targeted delivery platform.

Panlin Capital’s biomedical investment team believes that,Hangzhou Dina Yuansheng Biotechnology Co., Ltd.’s targeted delivery system based on nucleic acid nanocarriers demonstrates technological leadership. From a technical perspective, the company’s foundational technology stems from its founder’s early research on DNA nanocarriers during his doctoral studies, which was subsequently expanded under his leadership to include functional exploration at the animal level. Within just over a year of establishment, the company has developed a relatively comprehensive manufacturing process system, conducted extensive safety validations for its carriers, and established a tiered pipeline strategy by integrating unmet clinical needs with the advantages of its technology platform. Dr. Ding, the founder, possesses many years of R&D experience in the field of DNA nanocarriers and has a profound understanding of their design and application. Leveraging this expertise alongside the rich industry and corporate management experience of the company’s core team, Hangzhou Dina Yuansheng has the potential to become a leading enterprise in the field of DNA nano-delivery.

Li Yuhui, Founding Managing Partner of Panlin Capital, stated thatFrom the perspective of unmet clinical needs, there is substantial and clear demand for extrahepatic delivery and non-viral vector delivery. The DNA nanocarriers developed by Hangzhou Dina Yuansheng Biotechnology Co., Ltd. are poised to overcome the limitations of delivery technologies such as LNPs and GalNAc, enabling targeting across different organs and cell types. This represents a significant exploration by the company to achieve precise drug delivery and drive industry advancement. We are currently at a critical juncture where DNA nanotechnology is transitioning from scientific research to industrial commercialization. Panlin Capital is pleased to support Dr. Ding Baoquan’s team, which boasts profound expertise in the field of DNA nanocarriers. This investment reflects Panlin Capital’s commitment to “source innovation.” We look forward to seeing this technology undergo extensive clinical validation in the future. Panlin Capital will remain true to its mission as a venture capital firm, continuously leveraging its professionalism and experience to facilitate the clinical translation of cutting-edge life science technologies.